![Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-019-0727-7/MediaObjects/12874_2019_727_Fig4_HTML.png)
Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text
![Overall vs. Progression-Free Survival, Response Rates: Oncology Terminology 101 (by Oster Oncology) - YouTube Overall vs. Progression-Free Survival, Response Rates: Oncology Terminology 101 (by Oster Oncology) - YouTube](https://i.ytimg.com/vi/2vwNGJJRfZM/sddefault.jpg)
Overall vs. Progression-Free Survival, Response Rates: Oncology Terminology 101 (by Oster Oncology) - YouTube
![Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-019-0727-7/MediaObjects/12874_2019_727_Fig2_HTML.png)
Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text
![Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2015/jco.2014.58.33.issue-9/jco.2014.59.0489/20161107/images/medium/zlj00915-5060-t01.jpeg)
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
![Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2015/jco.2014.58.33.issue-9/jco.2014.59.0489/20161107/images/medium/zlj00915-5060-t02.jpeg)
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
KAZIA PRESENTS FURTHER PAXALISIB AND CANTRIXIL DATA AT AACR, REINFORCING POSITIVE EFFICACY SIGNALS FOR BOTH DRUGS
![Response rates Overall response rate and depth of response according to... | Download Scientific Diagram Response rates Overall response rate and depth of response according to... | Download Scientific Diagram](https://www.researchgate.net/publication/341590087/figure/fig3/AS:958461890281480@1605526530128/Response-rates-Overall-response-rate-and-depth-of-response-according-to-renal-function-in.png)